What Teva's $1.2bn settlement means for pay for delay

Drug manufacturer giant Teva was practically at the courthouse steps when it settled on 28 May for $1.2bn with the US Federal Trade Commission (FTC) over what the agency said were illegal efforts by the company's subsidiary Cephalon to block US generic competition of its $1bn blockbuster narcolepsy and sleep apnea drug Provigil (modafinil).